Kaken Pharmaceutical Co's Total Assets for the quarter that ended in Dec. 2023 was 円168,337 Mil.
During the past 12 months, Kaken Pharmaceutical Co's average Total Assets Growth Rate was 5.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 2.90% per year.
During the past 5 years, the average Total Assets Growth Rate was -1.70% per year.
During the past 10 years, the average Total Assets Growth Rate was -0.20% per year.
During the past 13 years, Kaken Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 5.80%. The lowest was -4.80%. And the median was 0.80%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Kaken Pharmaceutical Co's Total Assets for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co (TSE:4521) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Kaken Pharmaceutical Co's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Kaken Pharmaceutical Co Total Assets Related Terms
Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Kaken Pharmaceutical Co (TSE:4521) Business Description
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4521 has been successfully added to your 